Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
BioLineRx Ltd. has reported a successful first quarter in 2024, with a notable uptake of their newly approved therapy APHEXDA® and progress on its oncology and rare disease portfolio. The company is on course to meet its target of securing APHEXDA® formulary placement in top transplant centers and has presented encouraging data from its pancreatic cancer trials. Additionally, BioLineRx has secured substantial financing to support the commercialization of APHEXDA® and further development activities.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.
